Diverse building blocks Iris Biotech offers a broad portfolio of protected amino acids, coupling reagents, linkers, resins, natural and unusual amino acids and derivatives, fatty acid derivatives, and thousands of other building blocks. This positions them as a one-stop supplier for peptide modification projects, suggesting cross-sell opportunities across drug discovery, delivery, and life science research needs.

PROTAC and Linkerology With new sections like Linkerology and PROTAC building blocks, Iris Biotech targets emerging drug discovery modalities. This creates upsell potential with customers pursuing targeted protein degradation and advanced linkers, including predefined breaking points and stability, appealing to teams exploring novel therapeutic modalities.

PEGylation leadership Their world’s largest portfolio of PEGylation reagents, ranging from short hydrophilic linkers to long, complex derivatives, supports developers in DARPA-like or biologics projects requiring bioconjugation. This is a strong entry point for sales conversations with biotech companies focusing on protein modification, half-life extension, and delivery systems.

Recent product launches Recent innovations such as CliCr cyclic alkyne for metal-free click chemistry, Smoc amino acids for aqueous SPPS, and new amino acid derivatives indicate ongoing R&D and productization. This suggests opportunities to engage R&D teams early, offering trials, custom synthesis, and collaboration on pilot projects.

Strategic collaborations Active participation in conferences (e.g., Nanomaterials for Tumor Immunotherapy) and growth in life sciences product areas (inhibitors, metabolites, fluorescent dyes) signal a customer-facing approach and potential partnerships. This presents openings for co-marketing, sponsored research, and long-term supply agreements with academic and industry partners.